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 Posterior polymorphous corneal dystrophy (PPCD;
OMIM 122000, 609140, and 609141) is an autosomal domi-
nant endothelial corneal dystrophy characterized by vesicular
lesions and epithelial-like changes of the corneal endothelium.
PPCD shows variable expressivity [1,2] and while most cases
are mild; severe cases require corneal transplantation (about
11%) [3]. PPCD is an important indication of penetrating
keratoplasty for congenital corneal opacities and a significant
risk factor for the development of glaucoma [4,5].
PPCD is genetically heterogeneous with linkage reported
to three different loci [6-8] and evidence for further locus het-
erogeneity [9]. PPCD1 (OMIM 122000) was mapped to a 30
cM pericentromeric region on chromosome 20 (between
D20S98 and D20S108) using a large three generation family
[6]. This interval includes the 2.7 cM region for autosomal
dominant congenital hereditary endothelial dystrophy
(CHED1; OMIM 121700) [10], suggesting that the two con-
ditions might be allelic variants.
VSX1, a paired-like homeobox transcription factor in the
PPCD1 disease interval, is an attractive positional and func-
tional candidate gene. Different groups have reported muta-
tions involving functional domains of VSX1 in patients affected
with PPCD [11,12], keratoconus [11,13], or a combination of
both phenotypes [11,14]. However, unresolved issues remain
concerning the pathogenic role of VSX1 in PPCD. This gene
was not shown to be expressed in adult human cornea
[11,15,16]. Mice with null alleles do not show any corneal
abnormalities [17]. In addition, no mutations were detected in
the family used for mapping the PPCD1 locus (Zmax= 5.54 at
θ= 0 for marker D20S45) [6,11].
Failure to detect a pathological sequence variant by mu-
tational analysis of the coding sequence (exons 1-5) of VSX1,
a key candidate gene, in the original PPCD1-linked families
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Purpose: Posterior polymorphous corneal dystrophy (PPCD) is a genetically heterogeneous autosomal dominant condi-
tion which maps to the pericentromeric region of chromosome 20. Mutations in the VSX1 transcription factor have been
reported in patients affected with PPCD, keratoconus, or a combination of both phenotypes. However, no mutation was
identified in the coding region of VSX1 in the family used for the original mapping. To clarify the genetic basis of PPCD1,
a thorough analysis was performed on the original PPCD1 family and two other PPCD1-linked families. As part of the
analysis, the expression profile, transcript variants, and evolutionary conserved regions of VSX1, a key candidate gene
within the linkage interval, were characterized.
Methods: Haplotype analysis was performed using highly informative markers on the pericentromeric region of chromo-
some 20. VSX1 transcript variants were identified using RT-PCR and characterized by 3’RACE assay. Temporal expres-
sion profile of VSX1 was evaluated using semi-quantitative real-time RT-PCR on human tissues. Evolutionary conserved
regions (ECRs) were identified in the vicinity of VSX1 using publicly available sequence alignments (UCSC and rVista)
and sequenced for mutation analysis.
Results: Recombination events were identified that narrow the PPCD1-disease interval from 20 to 16.44 cM. This smaller
interval includes the CHED1 locus and a recently described PPCD locus in Czech families. The three strongest candidate
genes of the PPCD1-CHED1 overlap region (RBBP9, ZNF133, SLC24A3) did not show any mutations in our PPCD1-
linked families. Semi-quantitative real-time RT-PCR detected VSX1 expression in neonatal human cornea. Six transcript
variants of VSX1 were characterized. Four of the transcript variants spliced to two novel exons downstream of the gene.
Mutation analysis of the PPCD1-linked families did not reveal any mutations in the full genomic sequence of VSX1
(considering all splice variants) or in the six cis- regulatory modules predicted in the vicinity of VSX1 (100 kb).
Conclusions: This is the first documentation of VSX1 expression in human neonatal cornea. We provide evidence for
genetic heterogeneity of chromosome 20-related PPCD and refinement of the original PPCD1 interval. The full genomic
sequence of VSX1 and coding exons of three other candidate genes were excluded from being pathogenic in the original
PPCD1 family.
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71[6,11] prompted our group to characterize expression profile
and regulatory elements of this gene to identify novel VSX1
genomic sequences for analysis. We addressed the controversy
over corneal expression of VSX1 by performing a temporal
expression analysis in human samples that showed perinatal
expression of this gene in human cornea. To address the ge-
netic basis of disease in PPCD1-linked families, we further
investigated the pathogenic role of VSX1, considering differ-
ent possible mutation mechanisms involving previously
uncharacterized transcript variants or regulatory elements.
Finally, further mapping of the disease interval in PPCD1-
linked families, with or without a VSX1 mutation, suggests
genetic heterogeneity at the PPCD1 locus.
METHODS
Human subjects identification:  The project was approved by
The Hospital for Sick Children Research Ethics Board and
was conducted in accordance with the tenets of the Declara-
tion of Helsinki. All participating patients signed an informed
consent. Patients were recruited through the ocular genetics
clinic of the Hospital for Sick Children and by international
collaborators.
Three PPCD affected families with evidence of linkage
to PPCD1 were included in the study. The original mapping
study of PPCD1 was conducted on family 1 [6]. Family 2 was
also linked to PPCD1 (unpublished data). Family 3 was the
first PPCD affected family with a VSX1 mutation identified
(G160D) [11]. No VSX1 mutation had been identified in fami-
lies 1 or 2 [11].
RNA extraction:  Human eyes or corneas of different ages
(12 weeks of gestation to 64 years) were collected within 24 h
postmortem from the Eye Bank of Canada (Ontario Division)
or a local abortion clinic and preserved in RNALater™
(Ambion, Austin, TX). After rapid dissection, total RNA was
isolated using TRIzol® reagent (Invitrogen, Burlington,
Canada). DNA contamination was removed by RNase-free
DNase I treatment (Roche, Laval, Canada).
Real-time semi-quantitative RT-PCR:  One µg of total
RNA was reverse transcribed (SuperScript™ II First-Strand
Synthesis, Invitrogen) using random hexamers. Melanin inhi-
bition of RT-PCR was reversed by adding 20 µg of BSA (New
England Biolabs, Ipswich, MA) to the reaction after primary
denaturation [18].
Real-time PCR was conducted according to standard
guidelines (Brilliant® SYBR® Green qPCR Master Mix,
Stratagene, La Jolla, CA; Abi Prism® 7500-HT, Applied
Biosystems, Foster City, CA). Dissociation curve analysis of
amplification products was performed to confirm presence of
a single product. To maintain consistency, baseline and thresh-
old values were set automatically by the data analysis soft-
ware (SDS v2.1, Applied Biosystems). To standardize the
amount of cDNA in each reaction, an endogenous reference
gene was used as internal control. Relative expressions were
calculated based on the Ct values according to models previ-
ously described [19].
Rapid amplification of cDNA ends (RACE):  3' RACE
was performed on 1 µg of total retinal RNA (extracted from
adult human retina) using FirstChoice® RLM-RACE kit
(Ambion) according to standard guidelines [20,21]. Primers
used are shown in Table 1 (PCR conditions are available upon
request). Final PCR products were electrophoresed on 2% siev-
ing agarose gels. All major visible DNA bands were gel puri-
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TABLE 1. SEQUENCE OF OLIGONUCLEOTIDE PRIMERS
Sequences of other primers will be available upon request. *g.s.: gene specific.
72fied (MinElute® or QIAquick Gel Extraction, Qiagen,
Mississauga, Canada), ligated into a T-vector (pGEM® T-Easy
Vector, Promega, Madison, WI) and transformed into Com-
petent E.coli (Subcloning Efficiency™ DH5α™, Invitrogen).
Plasmid DNA was extracted from positive clones (QIAprep®
Miniprep, Qiagen). The presence of expected inserts was con-
firmed by enzymatic digestion (EcoRI or EagI, New England
Biolabs) before bidirectional sequencing using T7 and SP6
primers. Sequence files for each clone were then assembled
into a single FASTA file (CAP3 software provided in the pub-
lic domain by PBIL) [22] and aligned against the genomic
sequence (NT_011387) using the mRNA-to-genomic align-
ment program Spidey (provided in the public domain by NCBI)
[23].
Whole genome amplification:  Genomic DNA was ex-
tracted from peripheral blood or buccal swabs [24,25]. In the
case of index families, DNA was amplified before application
in downstream assays using a φ29 polymerase based system
(GenomiPhi™, Amersham Biosciences, Piscataway, NJ) [26].
Whole genome amplification methods based on multiple dis-
placement provide a balanced representation of genome suit-
able for genotyping and sequencing [27,28].
DNA sequencing:  DNA fragments of interest were PCR-
amplified [21,29] and purified (QIAquick PCR Purification,
Qiagen) before cycle sequencing and sequence analysis as
described elsewhere [30].
Short tandem repeat polymorphism (STRP) genotyping:
DNA (20-50 ng) from selected individuals were PCR-ampli-
fied, denatured, electrophoresed and detected on an automated
sequencer (ALF™, Pharmacia Biotech AB, Uppsala, Sweden).
Genotypes were determined by software analysis (Fragment
Manager v1.1, Pharmacia LKB Biotechnology, Uppsala, Swe-
den).
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Figure 1. Relative expression of VSX1 in a panel of eye tissues of differnet ages.  Each bar represents the relative expression of VSX1
normalized to GAPDH in a different tissue/age; mean±SD (Sc: sclera, Co: cornea, Ir: iris, CB: ciliary body, Len: lens, Cho: choroid, Ret:
retina, ONH: optic nerve head). Numbers above each bar are the average level of expression relative to neonatal retina obtained from tripli-
cates of the experiment. Numbers on the x-axis are the age of donor individuals (w: fetal week, y: year, m: month, d: day). Data for corneal
samples is shown expanded in the inset.
Figure 2. Photograph of ethidium bromide stained 3’RACE products
electrophoresed on a 2% sieving agarose gel.  Numbers on the left
show the sizes of molecular marker (M) bands in bp. Numbers on the
right correspond to different VSX1 transcript variants.
73RESULTS
Temporal expression profile of human VSX1: To elucidate the
temporal expression profile of VSX1 in the cornea, semi-quan-
titative RT-PCR was performed on a panel of human eye tis-
sues (adult, neonatal, and fetal). To select the least variable
internal control gene, a validation strategy based on the geo-
metric average of multiple control genes was used [31]. Of
the housekeeping genes tested (ACTB, GAPDH, and
Cyclophilin A), GAPDH was selected as the reference gene
since it showed the lowest variation (geometric average of
1.401). The experiment was repeated three times in triplicate
with each cDNA sample. Figure 1 shows the expression pro-
file of VSX1 based on relative comparative fold to the house-
keeping gene. Real-time PCR on human ocular tissues con-
firmed expression of VSX1 in neonatal but not in adult cornea.
The highest expression was in retina and in the neonatal pe-
riod. Lens and neonatal cornea show the lowest levels of ex-
pression. No expression was detected in the sclera or in the
adult and early fetal cornea (less than or equal to 20 weeks).
Characterizing VSX1 transcript variants:
EST alignments available in the UCSC genome browser
and exon predictions based on EST clustering, such as ECgene
v1.2 and AceView, provided evidence of novel exons down-
stream to VSX1. This was confirmed by RT-PCR on human
adult retinal RNA using primers in predicted exons that pro-
duced PCR products of expected sizes.
To identify different mRNA classes transcribed from the
VSX1 gene, a 3’RACE experiment was performed on human
adult retinal total RNA. Nested PCR using gene specific prim-
ers (Table 1, 3OA and 3IA) consistently yielded six
polyadenylated products on gel electrophoresis (Figure 2).
Duplication of the experiment using another set of primers
(Table 1, 3OB and 3IB) produced similar results (data not
shown). Sequence analysis of the 3’RACE product clones
consistently revealed two novel downstream exons for VSX1,
exon 6 and exon 7. Exon 6, 108 bp in length, is located at
position 24993279-24993172 on genomic contig NT_011387.
Exon 7 spans 535 bp of genomic DNA at position 24992119-
24992654 (NT_011387). These two exons were mainly non-
coding, not highly conserved and alternatively spliced in dif-
ferent VSX1 transcripts. Including these novel exons, the VSX1
gene now spans 10.65 kb of genomic DNA (former genomic
size 6.7 kb).
The full cDNA sequence for each of the transcript vari-
ants was deposited in GenBank (DQ854807 to DQ854812).
Sequence of the 5’end of transcripts (5’UTR, exon 1 and 5'
end of exon 2) was obtained using previously reported VSX1
sequence (GenBank NM_014588). Transcript variants 1 and
2 (GenBank NM_014588 and NM_199425) were previously
described (Figure 3A) [32]. Transcripts 3 to 6 are novel (Fig-
ure 3B).
Transcript 1 has the longest ORF, encoding a 365 residue
protein (38.43 kDa) containing homeodomain (HD), CVC
(Chx10, Vsx1 and ceh-10) and RV (RINX and Vsx1) domains
and additional motifs previously described [32]. Other tran-
scripts result in truncated protein products lacking RV domain,
part or the whole CVC domain and sometimes the carboxyl
end of the HD. The most carboxyl ends of these truncated
polypeptides show no significant homology (Figure 4) to any
known protein domains (Pfam software, provided in the pub-
lic domain by the Sanger institute).
Predicting cis-regulatory modules: To identify conserved
non-genic sequences (CNGs) potentially related to VSX1, 110
kb of genomic sequence (50 kb upstream and downstream of
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Figure 3. The mRNAs transcribed from the human VSX1 gene.  A: Previously described; B: novel transcript variants. Exons are numbered
from 1 to 7. Black boxes indicate coding sequences; thin broken lines indicate spliced intronic sequences; gray boxes indicate untranslated
regions. Numbers on the right show the length of each transcript variant as determined from the +1 position.
74the gene; chr20:24,950,120-25,060,767; UCSC hg17) was
compared with orthologous sequences in 9 non-human verte-
brates (dog, mouse, rat, opossum, chicken, frog, Tetraodone,
zebrafish and Fugu). Publicly available, gapped and ungapped
alignments available at Vista genome (provided in the public
domain by the Genomics Division of Lawrence Berkeley Na-
tional Laboratory) and ECR (provided in the public domain
by the Dcode.org Comparative Genomics Center) browsers
were used [33-35]. The analysis was performed under the es-
tablished parameters for CNGs (70% identity in 100 bp win-
dow) [36,37]. These criteria revealed five upstream and one
downstream evolutionary conserved regions (ECRs) with con-
servation between the human reference and multiple (at least
three) other non-primate vertebrate lineages. Other ECRs in
this region physically overlap exons of VSX1 or the adjacent
gene (ACAS2L). These six ECRs (5+1) are most likely non-
coding as no corresponding spliced ESTs were detected (Table
2). This approach for identification of ECRs has been vali-
dated and established for identifying sequences with slower
evolution than the average neutral rate [36].
Predicted ECRs consistently overlapped conserved tran-
scription factor binding site (TFBS) clusters predicted by rVista
2.0 program (pre-computed annotation of ECR browser) [38].
Overlap with TFBSs supports the functional role of predicted
ECRs. The conserved nature of these TFBS clusters suggests
these could be cis-regulatory modules (CRMs) regulating VSX1
expression.
Mutation analysis of VSX1 and related ECRs: Mutation
analysis of VSX1 in the family used for mapping PPCD1 lo-
cus (Family 1) as well as 2 other families suggested to be linked
to PPCD1, included the five known exons, the two novel ex-
ons 6 and 7, and the end part of exon 3 specific to transcript
variant 2 (exon 3b in Figure 3A) was carried out. No change
was identified in selected individuals sequenced from these
families.
We expanded our mutation analysis to include the ECRs
around VSX1. Mutational analysis of amplicons containing the
six identified ECRs (see above) failed to show mutations in
Families 1 and 2. Three previously described SNPs were ob-
served in Family 1. rs6050337 with a minor allele frequency
of 0.267 (dbSNP) was identified in R4 (heterozygous). Minor
alleles of two other SNPs (rs2224072 and rs4141461) were
observed as homozygous in R3. None of the identified SNPs
cosegregate with the disease status.
Fine mapping of the PPCD1 critical region:  No VSX1
disease-causing mutations were found in the two PPCD fami-
lies (Families 1 and 2) initially used for mapping the disease
to chromosome 20. The 20 cM critical disease interval de-
scribed by Héon et al. [6] also included ID1, a developmen-
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Figure 4. Schematic representation of VSX1 protein isoforms.  Conserved domains of VSX1 and the numbered amino acid residues compris-
ing each domain are indicated. The numbers on the right show total length of each isoform. N and C are amino and carboxyl termini of the
isoforms. (NLS: nuclear localization signal; CVC: Chx10, Vsx1, ceh-10 domain; RV: RINX, Vsx1)
TABLE 2. AMPLICONS CONTAINING ECRS IN THE VICINITY OF VSX1
Sequence positions refer to the May 2004 release of human refer-
ence sequence (NCBI build 35).
75tally important dominant negative helix-loop-helix protein
which did not show any mutation of the coding sequence in
these families (unpublished data).
Therefore, mapping of the disease interval was refined
for families 1 and 3 (Figure 5 and Figure 6). Family 2 (not
shown) could not be used for narrowing down the interval
due to the poor family structure (DNA available from 2 af-
fected individuals). In Family 1 (Figure 5) recombination
events narrowed down the critical interval to 16.44 cM (about
21.55 Mb). Further genotyping of family 3 (even though known
to carry two VSX1 changes; Figure 6) [11] narrowed the dis-
ease interval to 6.57 cM (about 14.8 Mb).
There was no evidence of haplotype sharing between these
families (data not shown). Figure 7 schematically summarizes
the disease intervals for the PPCD1 families described to date
including our recent data. These data suggest heterogeneity at
PPCD1 locus by breaking it to two intervals. The disease in-
terval for family 3, known to have a VSX1 mutation, is defi-
nitely distinct from the CHED1-PPCD1 overlap interval de-
scribed in Czech families (see discussion) [39].
Mutation analysis of candidate genes from PPCD1-
CHED1 interval:  Genes in the PPCD1-CHED1 overlap in-
terval were prioritized based on corneal expression and func-
tion. Available corneal EST and SAGE libraries were used as
the initial evidence of corneal expression. Expression was fur-
ther confirmed by RT-PCR on human corneal RNA [40-43].
The strongest three candidate genes included RBBP9, ZNF133,
and SLC24A3 (see discussion). We analyzed the coding se-
quence of these genes in individuals from both families (1
and 2) which did not reveal any mutation. Sequence analysis
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Figure 5. Pedigree structure of family 1 and its haplotype analysis at PPCD1 locus.  This family was originally used to map PPCD to the
chromosome 20 locus [6]. No VSX1 mutation has been identified in this family. Marker names are shown on the right. Genotypes of each
individual are shown as numbers underneath the individual’s symbol. Dark bars represent the inferred disease haplotype with recombinations
of parental chromosome shown.
76included the first seven exons of SLC24A3 located in the
PPCD1-CHED1 overlap interval.
DISCUSSION
 Our study is the first documentation (and assessment) of VSX1
expression in neonatal human cornea. This observation is sig-
nificant since the role of VSX1 as a candidate gene was ques-
tioned, partly due to its expression profile [44]. VSX1 expres-
sion was proposed to be exclusive to a subset of inner nuclear
layer cells of retina and absent from the adult human or devel-
oping mouse cornea [11,15,32]. The results from our study
supported the findings of two recent murine studies [16,45]
showing corneal expression of VSX1.The VSX1 expression
seems to be restricted to the perinatal period, which is consis-
tent with the current hypothesis that PPCD-related abiotro-
phy begins during perinatal endothelial differentiation [46].
Electron microscopic studies on Descemet’s membrane of
PPCD cases, provides evidence that the pathology arises at
gestation or shortly after birth [46,47].
We showed alternative splicing of VSX1 and character-
ized six different transcript variants for this gene. Five of the
six transcript variants identified encode truncated proteins.
Isoforms 2, 4, and 6 are not expected to bind the DNA effi-
ciently due to the lack of recognition helix of HD. Isoforms 3
and 6, which retain most of the DNA binding domains, should
have significant DNA binding activity. Alternatively spliced
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Figure 6. Haplotype analysis of family 3 at PPCD1 locus.  The fam-
ily has been fully described elsewhere [11] with mutations observed
in VSX1 coding sequence. Marker names are shown on the right.
Genotypes of each individual are shown as numbers underneath the
individual’s symbol. Dark bars represent the inferred disease haplo-
type with recombinations of parental chromosome shown.
Figure 7. Ideogram of chromosome 20 showing PPCD1 minimal dis-
ease interval in different families.  Bars on the left represent the dis-
ease intervals for PPCD1 and CHED1 as originally described [6,10].
Bars on the right show the refinements made in our study. Family 1
is the family used for mapping the locus (further refinement). Fam-
ily 3 is the family described by Heon et al. [11] with a known VSX1
mutation. Cz1 and Cz2 represent Czech families described by
Gwilliam et al. [39].
77transcripts encoding truncated isoforms have been described
in several homeodomain genes [48-51]. The functional sig-
nificance of VSX1 truncated isoforms remains unclear. How-
ever, since all of these isoforms retain the proline-rich and
acidic domains for transcriptional activation, they may modu-
late the transcriptional activity of the full-length protein by
competing for co-activators or co-repressors. Another possi-
bility is having independent developmental functions, through
a mechanism other than DNA binding [50].
A thorough mutation analysis of novel VSX1 exons and
ECRs in the vicinity of the gene in the original PPCD1 family
failed to reveal any disease causing mutation. It seems that
VSX1 plays a pathogenic role only in a subgroup of PPCD1
mapped families. VSX1 changes observed in Family 3 were
considered biologically significant (conservation and segre-
gation with the disease status) [11] and convincing VSX1 mu-
tations have been reported in PPCD families from other groups
[12-14]. Nonetheless, not identifying a disease-associated mu-
tation in VSX1’s genomic sequence, different transcript vari-
ants and regulatory elements, in some chromosome 20-linked
PPCD families (including family 1) suggests that another gene
may be involved [11,39].
Fine mapping of the disease interval in the family with an
identified VSX1 mutation (Family 3) showed that the smallest
disease interval in this family is distinct from one of the re-
ported Czech families [39], suggesting genetic heterogeneity
of the original PPCD1 locus (Figure 7).
Autosomal dominant CHED (CHED1) and PPCD share
several clinical, histopathologic, and immunohistochemical
features, which suggest that these two conditions could be al-
lelic variants. Overlap of PPCD1 and CHED1 loci (especially
in the Cz2 family) is consistent with this concept of clinical
heterogeneity [10,52]. This suggests that CHED1 may be a
locus for a second PPCD gene on chromosome 20.
No other human ocular phenotype maps to the new
PPCD1-CHED1 minimal disease interval (20p11.23-p12.1;
OMIM, provided in the public domain by NCBI). Three ocu-
lar phenotypes (corneal disease-1, corneal disease 1- 2 Jack-
son, and blind-sterile) map to the syntenic region in the mouse
genome on the distal part of chromosome 2 (Mouse Genome
Informatics, provided in the public domain by the Jackson
Laboratory). None of these conditions have direct relevance
to corneal endothelium [53-55]. This interval contains more
than 20 genes, some of which are interesting candidate genes
based on expression and functional evidences.
We excluded the coding sequence of three additional can-
didate genes in our families. RBBP9 (retinoblastoma binding
protein 9), with high expression in corneal endothelium [40],
has been shown to be important in the transformation process
via its capacity to confer resistance to the growth-inhibitory
effects of TGF-β1 [56]. PPCD occurs in consequence of meta-
plasia from a non-proliferating endothelium to an expanding
epithelium. Interestingly, there is compelling evidence that the
arrest of normal endothelium in the G1-phase of cell cycle is
partly regulated by TGF-β (both β1 and β2) [57] which is
known to be expressed by cultured human endothelial cells
[58-60] and in aqueous humor [61-63]. ZNF133, a transcrip-
tional repressor containing KRAB box and zinc finger domains
[64,65], is a strong candidate gene with corneal expression
[41,43,66,67]; since another zinc finger protein (TCF8) has
been associated with PPCD [45]. SLC24A3 (solute carrier fam-
ily 24 member 3) shows corneal expression [68]. The interest
in this K+-dependent Na+/Ca2+ exchangers is related to the re-
cent association of another solute carrier (SLC4A11) with au-
tosomal recessive CHED [69,70].
Endothelial corneal dystrophies are significant causes of
visual impairment that would benefit from further molecular
characterization. However, elucidation of the genetic basis of
chromosome 20-related PPCD will require larger patient co-
horts to fully evaluate the role of the regulatory elements and
isoforms of VSX1 as well as to validate the role of other muta-
tional events or disease-associated genes.
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